Helmholtz Centre for Infection Research (HZI), Biogenic Nanotherapeutics Group (BION), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, Saarbrücken 66123, Germany; Department of Pharmacy, Saarland University, Campus E8.1, Saarbrücken 66123, Germany.
CDL Research, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands; Department of Experimental Cardiology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Adv Drug Deliv Rev. 2021 Jun;173:416-426. doi: 10.1016/j.addr.2021.03.020. Epub 2021 Apr 6.
Extracellular vesicles (EVs) are cell-derived nanoparticles that are important mediators in intercellular communication. This function makes them auspicious candidates for therapeutic and drug-delivery applications. Among EVs, mammalian cell derived EVs and outer membrane vesicles (OMVs) produced by gram-negative bacteria are the most investigated candidates for pharmaceutical applications. To further optimize their performance and to utilize their natural abilities, researchers have strived to equip EVs with new moieties on their surface while preserving the integrity of the vesicles. The aim of this review is to give a comprehensive overview of techniques that can be used to introduce these moieties to the vesicle surface. Approaches can be classified in regards to whether they take place before or after the isolation of EVs. The producing cells can be subjected to genetic manipulation or metabolic engineering to produce surface modified vesicles or EVs are engineered after their isolation by physical or chemical means. Here, the advantages and disadvantages of these processes and their applicability for the development of EVs as therapeutic agents are discussed.
细胞外囊泡 (EVs) 是细胞来源的纳米颗粒,是细胞间通讯的重要介质。这种功能使它们成为治疗和药物输送应用的理想候选者。在 EVs 中,哺乳动物细胞衍生的 EVs 和革兰氏阴性细菌产生的外膜囊泡 (OMVs) 是最受关注的药物应用候选者。为了进一步优化它们的性能并利用它们的天然能力,研究人员一直在努力在保持囊泡完整性的同时在其表面上配备新的部分。本综述的目的是全面概述可用于将这些部分引入囊泡表面的技术。这些方法可以根据它们是在 EVs 分离之前还是之后进行分类。可以对产生细胞进行遗传操作或代谢工程处理,以产生表面修饰的囊泡,或者可以通过物理或化学手段在分离后对 EVs 进行工程改造。在这里,讨论了这些过程的优缺点及其在开发作为治疗剂的 EVs 方面的适用性。